Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis

Madrid, Félix Fernández

doi:10.1016/j.canlet.2004.12.017

Cited by 106 publications

(94 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These autoantibodies have been detected in several human cancers, and significant advances have been made in the identification of their target antigens, particularly in lung cancer (28,30), colorectal cancer (36), breast cancer (29), prostate cancer (27,37), leukemia (26), non-Hodgkin lymphoma (24), hepatocellular carcinoma (25,32,34), ovarian cancer (31), pancreatic cancer (33,38), and paraneoplastic neurological syndromes (35). Although the mechanisms leading to autoantibody production in cancer patients are not clearly understood, emerging evidence indicates that most TAAs are cellular proteins whose aberrant regulation or function could be linked to malignancy (3).…”

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

“…Although the mechanisms leading to autoantibody production in cancer patients are not clearly understood, emerging evidence indicates that most TAAs are cellular proteins whose aberrant regulation or function could be linked to malignancy (3). For instance, TAAs include known oncoproteins such as HER-2/ Neu and c-MYC (46 -49); tumor suppressor proteins such as p53 (50); survival proteins such as survivin and lens epithelium-derived growth factor (LEDGF/p75) (27,51); cell cycle regulatory proteins such as cyclin B1 (52); mitosis-associated proteins such as centromere protein F (CENP-F) (25,53,54); chromatin-associated proteins such as topoisomerases (29,55); mRNA-binding proteins such as p62, IMP1, and Koc (56,57); and differentiation and cancer testis antigens such as NY-ESO-1 (58).…”

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

“…For example, the rapamycin-sensitive mTOR (mammalian target of rapamycin) phosphorylation pathway has been implicated in the pathogenesis of breast cancer, and members of this pathway are targeted by autoantibodies in patients with breast cancer (29). These include ribosomal protein S6, eukaryotic elongation factor 2, eukaryotic elongation factor 2 kinase, and heat shock protein 90 (HSP90).…”

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

“…These include ribosomal protein S6, eukaryotic elongation factor 2, eukaryotic elongation factor 2 kinase, and heat shock protein 90 (HSP90). Autoantibodies in breast cancer also recognize components of the DNA repair pathway such as the Ku protein, topoisomerase I, and the 32-kDa subunit of replication protein A (29). It should be noted that replication protein A interacts with the DNA repair and tumor suppressor proteins BRCA1 and BRCA2 (65,66).…”

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

“…Immunoreactive proteins that exhibit specific reactivity with cancer sera are then identified by MS. Various groups have used SERPA to identify candidate TAAs associated with breast cancer, including the RNA-binding protein regulatory subunit (RS), DJ-1 oncogene, glucose-6-phosphate dehydrogenase, heat shock 70-kDa protein 1 (HS71), and dihydrolipoamide dehydrogenase (8,29,134,135). Interestingly, although glucose-6-phosphate dehydrogenase is widely expressed in normal cells, the breast cancer sera reacted preferentially with some isoforms of the protein detected by MS, suggesting that autoantibodies in these sera might be driven by posttranslational modifications (8), which is consistent with previous observations that intracellular proteins targeted by autoantibodies in systemic autoimmune diseases often undergo these modifications (41).…”

Section: Identification and Validation Of Taamentioning

confidence: 99%

See 4 more Smart Citations

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer

Casiano

Mediavilla-Varela

Tan

2006

Molecular & Cellular Proteomics

122

106

View full text Add to dashboard Cite

The recognition that human tumors stimulate the production of autoantibodies against autologous cellular proteins called tumor-associated antigens (TAAs) has opened the door to the possibility that autoantibodies could be exploited as serological tools for the early diagnosis and management of cancer. Cancer-associated autoantibodies are often driven by intracellular proteins that are mutated, modified, or aberrantly expressed in tumor cells and hence are regarded as immunological reporters that could help uncover molecular events underlying tumorigenesis. Emerging evidence suggests that each type of cancer might trigger unique autoantibody signatures that reflect the nature of the malignant process in the affected organ. The advent of novel genomic, proteomic, and high throughput approaches has accelerated interest in the serum autoantibody repertoire in human cancers for the discovery of candidate TAAs. The use of individual anti-TAA autoantibodies as diagnostic or prognostic tools has been tempered by their low frequency and heterogeneity in most human cancers. However, TAA arrays comprising several antigens significantly increase this frequency and hold great promise for the early detection of cancer, monitoring cancer progression, guiding individualized therapeutic interventions, and identification of novel therapeutic targets. Our recent studies suggest that the implementation of TAA arrays in screening programs for the diagnosis of prostate cancer and other cancers should be preceded by the optimization of their sensitivity and specificity through the careful selection of the most favorable combinations of TAAs.

show abstract

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

Section: Cancer-associated Autoantibodies As Reporters Of Tumorigenesismentioning

confidence: 99%

Section: Identification and Validation Of Taamentioning

confidence: 99%

See 3 more Smart Citations

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer

Casiano

Mediavilla-Varela

Tan

2006

Molecular & Cellular Proteomics

122

106

View full text Add to dashboard Cite

show abstract

Advances in breast cancer screening modalities and status of global screening programs

Luo

Wang

Zhang

et al. 2022

Chronic Diseases and Translational Medicine

View full text Add to dashboard Cite

Breast cancer (BC) is the most prevalent malignancy worldwide, and a continued upward trend has been predicted in the coming decades. Screening in selected targeted populations, which is effective in reducing cancer‐related mortality, has been widely implemented in many countries. This review summarizes the advances in BC screening techniques, organized or opportunistic BC screening programs across different countries, and screening modalities recommended by different academic authorities. Mammography is the most widely used and effective technique for BC screening. Other complementary techniques include ultrasound, clinical breast examination, and magnetic resonance imaging. Novel screening tests, including digital breast tomosynthesis and liquid biopsies, are still under development. Globally, the implementation status of BC screening programs is uneven, which is reflected by differences in screening modes, techniques, and population coverage. The recommended optimal screening strategies varied according to the authoritative guidelines. The effectiveness of current screening programs is influenced by several factors, including low detection rate, high false‐positive rate, and unsatisfactory coverage and uptake rates. Exploration of accurate BC risk prediction models and the development of risk‐stratified screening strategies are highly warranted in future research.

show abstract

Development and characterization of polyspecific anti‐mitochondrion antibodies for proteomics studies on in toto tissue homogenates

et al. 2009

View full text Add to dashboard Cite

We describe the characterization of polyclonal antibodies directed against the whole mitochondrial subproteome, as obtained by hyperimmunization of rabbits with an organelle fraction purified from human skeletal muscle and lysed by sonication. After 2-DE separations with either blue native electrophoresis or IPG as first dimension and blotting, the polyspecific antibodies detect 113 proteins in human muscle mitochondria, representative of all major biochemical pathways and oxidative phosphorylation (OXPHOS) complexes, and cross-react with 28 proteins in rat heart mitochondria. Using as sample cryosections of human muscle biopsies lysed in urea/thiourea/CHAPS, the mitochondrial subproteome can be detected against the background of contractile proteins. When comparing with controls samples from mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes patients, immunoblotting shows in the latter a drastic reduction for the subunits of OXPHOS complex I as well as an increase of several enzymes, including ATP synthase. This finding is the first evidence at the proteomic level of massive up-regulation in a number of metabolic pathways by which the affected tissues try to compensate for the deficit in the OXPHOS machinery.

show abstract

Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis

Cited by 106 publications

References 92 publications

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer

Tumor-associated Antigen Arrays for the Serological Diagnosis of Cancer

Advances in breast cancer screening modalities and status of global screening programs

Development and characterization of polyspecific anti‐mitochondrion antibodies for proteomics studies on in toto tissue homogenates

Contact Info

Product

Resources

About